Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA extends PDUFA action date for dapagliflozin NDA

Oct. 27, 2011

Bionovo opens enrollment for pivotal trial of Menerba

Oct. 27, 2011

Poxel reports encouraging phase II data on imeglimin

Oct. 27, 2011

New glucagon receptor antagonists designed by Merck & Co.

Oct. 26, 2011

EMA begins new review of Protelos and Osseor

Oct. 26, 2011

Novel spider venom-derived contraceptive peptides designed in Chile

Oct. 25, 2011

CHMP maintains earlier opinion after reexamining Glybera MAA

Oct. 25, 2011

CHMP clarifies opinion on pioglitazone and the risk of bladder cancer

Oct. 24, 2011

Halozyme reports phase II data on ultrafast insulin analogue formulations

Oct. 24, 2011

Cytonet expands SELICA III study to Canada

Oct. 24, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...